Ventiv Scientific Achieves Landmark First-in-Human Success with V-PULSE Thrombectomy System

GTTP

V-PULSE System achieves successful first-in-human clinical cases for clot removal.
Novel technology offers real-time aspiration control at the catheter tip.
Designed to minimize catheter clogging and reduce procedural blood loss.
Enhances treatment options for thrombotic and embolic peripheral vascular diseases.

Impact - Why it Matters

Ventiv Scientific's V-PULSE system's successful first-in-human trials mark a significant leap in thrombectomy. Its real-time aspiration control promises enhanced procedural efficiency, reduced complications, and ultimately, improved patient outcomes for critical vascular conditions. This innovation could redefine clot removal standards, offering physicians superior control and minimizing risks.

Summary

Ventiv Scientific recently announced the successful completion of its first-in-human (FIH) clinical cases for the V-PULSE™ Mechanical Thrombectomy System. This novel platform is specifically designed to efficiently remove blood clots from the peripheral vasculature. Mechanical thrombectomy is a critical treatment for patients suffering from thrombotic and embolic vascular diseases, vital for restoring blood flow, relieving symptoms, preserving limbs, and saving lives in conditions like Deep Vein Thrombosis (DVT) and Acute Limb Ischemia (ALI).

The V-PULSE system introduces a significant advancement by providing physicians with real-time, precise control over aspiration force directly at the catheter tip. Unlike conventional systems, V-PULSE allows rapid initiation, cessation, and adjustment of aspiration, potentially minimizing catheter clogging and reducing procedural blood loss. Dr. Makmood Razavi praised its performance, stating it "removed significant clot burden...demonstrated excellent control and procedural efficiency," improving clot extraction and procedural control.

This successful milestone underscores Ventiv Scientific's dedication to innovative vascular intervention. The V-PULSE system expands their portfolio, complementing the FDA-cleared Control Aspire® Mechanical Thrombectomy System. Ventiv continues to develop next-generation technologies, aiming to enhance patient outcomes and expand treatment options for thrombotic disease globally.

Ventiv Scientific Achieves Landmark First-in-Human Success with V-PULSE Thrombectomy System

GTTP

V-PULSE System achieves successful first-in-human clinical cases for clot removal.
Novel technology offers real-time aspiration control at the catheter tip.
Designed to minimize catheter clogging and reduce procedural blood loss.
Enhances treatment options for thrombotic and embolic peripheral vascular diseases.